AIM ImmunoTech Inc (AIM)

Apr 29, 2026

AIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20 - MSN

Apr 29, 2026

Apr 29, 2026

AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill

Apr 29, 2026

Apr 28, 2026

AIM ImmunoTech Inc. Common Stock (NY: AIM - FinancialContent

Apr 28, 2026

Apr 22, 2026

AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Most Watched Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 20, 2026

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The National Law Review

Apr 20, 2026

Apr 18, 2026

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - ADVFN

Apr 18, 2026

Apr 17, 2026

AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com - Investing.com Australia

Apr 17, 2026

Apr 16, 2026

AIM ImmunoTech (AIM) Advances Pancreatic Cancer Treatment Plans - GuruFocus

Apr 16, 2026

Apr 16, 2026

AIM ImmunoTech IncExpects Next Duripanc St - Moomoo

Apr 16, 2026

Apr 16, 2026

AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer - Moomoo

Apr 16, 2026

Apr 16, 2026

AIM ImmunoTech advances Phase 3 planning for pancreatic cancer - Investing.com

Apr 16, 2026

Apr 16, 2026

AIM ImmunoTech Enters Pivotal Value Inflection Phase with - GlobeNewswire

Apr 16, 2026

Apr 15, 2026

AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment. - Bitget

Apr 15, 2026

Apr 14, 2026

AIM ImmunoTech Provides Routine Update on Annual Filings - ChartMill

Apr 14, 2026

Apr 13, 2026

AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative

Apr 13, 2026

Apr 13, 2026

Aim Immunotech Provides Routine Update On Annual Filings - TradingView

Apr 13, 2026

Apr 11, 2026

AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart

Apr 11, 2026

Apr 10, 2026

AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks

Apr 10, 2026

Apr 10, 2026

AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget

Apr 10, 2026

Apr 10, 2026

AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com Australia

Apr 10, 2026

Apr 10, 2026

AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView

Apr 10, 2026

Apr 10, 2026

AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan

Apr 10, 2026

Apr 10, 2026

AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan

Apr 10, 2026

Apr 10, 2026

Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

Apr 10, 2026

Apr 10, 2026

AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus

Apr 10, 2026

Apr 09, 2026

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - marketscreener.com

Apr 09, 2026

Apr 09, 2026

AIM ImmunoTech CEO to take live investor questions on April 16 - Stock Titan

Apr 09, 2026

Apr 08, 2026

AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 08, 2026

Apr 08, 2026

AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus

Apr 08, 2026

Apr 03, 2026

AIM Stock Analysis: AIM ImmunoTech Inc. hits 0.59 on 8.18 percent biotech rally - Xã Thanh Hà

Apr 03, 2026

Apr 02, 2026

AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 02, 2026

Apr 01, 2026

Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN

Apr 01, 2026

Apr 01, 2026

AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI

Apr 01, 2026

Apr 01, 2026

AIM Stock Analysis: AIM ImmunoTech Inc. biotech performance update at 0.59 after minor daily advance - Cổng thông tin điện tử Tỉnh Sơn La

Apr 01, 2026

Mar 28, 2026

AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart

Mar 28, 2026

Mar 27, 2026

AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets

Mar 27, 2026

Mar 27, 2026

AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

Mar 27, 2026

Mar 27, 2026

Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan

Mar 27, 2026

Mar 26, 2026

What's going on with AIM ImmunoTech stock Friday? - msn.com

Mar 26, 2026

Mar 26, 2026

AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 26, 2026

Mar 25, 2026

Earnings Scheduled For March 24, 2026 - Sahm

Mar 25, 2026

Mar 24, 2026

Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey

Mar 24, 2026

Mar 22, 2026

If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan

Mar 22, 2026